Benign Prostatic Hyperplasia Treatment Market Size & Trend Report, 2022-2030
According to Nova one advisor, the global Benign Prostatic Hyperplasia Treatment market was valued at USD 6.48 billion in 2021 and it is expected to hit around USD 12.9 billion by 2030 with a CAGR of 5.68% during the forecast period 2022 to 2030.
Benign Prostatic Hyperplasia Treatment Market Introduction
The prostate is a walnut-sized gland situated just below the bladder in front of the rectum and adjacent to the urethra as part of the male reproductive system. The prostate gland, which consists of four lobes (anterior, posterior, lateral, and medial), generates a fluid that combines with seminal vesicle secretions to generate most of the seminal fluid volume.
Benign prostatic hyperplasia (BPH) is a progressive disorder, wherein the prostate expands as part of the aging process or as a result of a disease. Incidence of benign prostatic hyperplasia increases significantly with age. Prostate development between puberty and the middle age is generally negligible. The exact cause of BPH is unknown, but the disease most frequently occurs in elderly males. It is probably caused due to hormonal changes. Several theories suggest that greater estrogen or dihydrotestosterone concentrations lead to hyperplastic development, although none are conclusive. The function of testosterone in BPH growth is still uncertain.
Currently, benign prostatic hyperplasia is one of the most common benign tumors observed in men across the globe. Benign prostatic hyperplasia is more prevalent in men aged 40 years and above. A study by the National Center for Biotechnology Information (NCBI) stated that the risk of benign prostatic hyperplasia is less common among the population of Asia than in the Caucasian population in the West. Around 50% of men below the age of 60 who underwent surgery for benign prostatic hyperplasia had a heritable form of the disease.
With progressively aging population and changing population profile in nearly all societies, benign prostatic hyperplasia is expected to become a major challenge for all health care systems. It is anticipated to become even more prevalent in men during the forecast period.
Report Scope of the Benign Prostatic Hyperplasia Treatment Market
|
Report Coverage |
Details |
|
Market Size |
USD 12.9 Billion by 2030 |
|
Growth Rate |
CAGR of 5.68% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
Treatment, End-user, and Region, |
|
Companies Mentioned |
|
Increase in Geriatric Population to Drive Demand for Benign Prostatic Hyperplasia Treatment
As per the benign prostatic hyperplasia treatment market analysis, increase in geriatric population is a major driver of the global market. Elderly individuals increase the patient pool in major regions of the world. According to the World Health Organization (WHO), the global geriatric population is likely to reach 2 billion (22% of the global population) by 2050 as against 962 million in 2017. The global geriatric population is expected to increase at the fastest rate in developed countries such as the U.S., the U.K., and Japan. Brazil, China, Thailand, and South Korea are likely to have a large geriatric population in the shortest span of time in the near future.
Surge in geriatric population is projected to propel the global benign prostatic hyperplasia treatment market size, as the population is more prone to various age-related as well as chronic diseases. The need for benign prostatic hyperplasia treatment among such patients is relatively higher. This is anticipated to drive the global benign prostatic hyperplasia treatment market.
Rise in Adoption of Minimally Invasive Surgeries to Propel Benign Global Prostatic Hyperplasia Treatment Market
Established types of minimally invasive surgery include electrocautery-based TURP, transurethral incision of the prostate (TUIP), and transurethral vaporization of the prostate (TUVP), although the latter technique is used infrequently. TURP is the most popular minimally invasive surgical procedure for relieving severe medical BPH symptoms, while radical prostatectomy based on open surgery is rarely used in the therapy of BPH, almost solely for indications of prostate cancer.
Adoption of minimally invasive surgeries has been increasing significantly due to various advantages such as less post-operative pain, less blood loss, reduced hospital stay, and faster recovery. This is likely to propel the global benign prostatic hyperplasia (BPH) treatment market during the forecast period.
Growth in Geriatric Population to Augment Global Benign Prostatic Hyperplasia Treatment Market
Prostate development is generally negligible between puberty and middle age; however, hormonal modifications could cause the gland to enlarge when a person reaches age 40 (for most males). Studies of autopsy have found the histological incidence of BPH. Thus, increase in geriatric population that is prone to urological diseases is projected to drive the benign prostatic hyperplasia (BPH) treatment market in the U.S.
Proven High Efficacy to Drive Alpha-blockers Segment
Alpha-blockers block0020alpha-adrenoceptors on the smooth muscle of the prostate, prostatic urethra, and bladder neck, leading to decreased muscle tone and reduction in the bladder obstruction. Alpha-blockers include alfuzosin hydrochloride (Uroxatral), silodosin (Rapaflo), tamsulosin hydrochloride (Flomax), and terazosin (Hytrin). Alpha-blockers are prescribed for men who have moderate to severe BPH symptoms. The proven high efficacy of alpha-blockers is expected to propel the alpha-blockers segment during the forecast period.
Most Preferred Approach for Benign Prostatic Hyperplasia Treatment Propelling TURP Segment
Currently, transurethral resection of the prostate (TURP) is the most preferred approach used by surgeons or urologists for benign prostatic hyperplasia treatment. TURP is an endoscopic electrosurgical procedure involving the removal of a portion of the prostate to relieve voiding obstruction associated with BPH. A specialized cystoscope known as a resectoscope is inserted into the urethra and threaded into the bladder. Following the procedure, most patients stay in the hospital between one and four days for observation. However, the trend is to perform TURP on an outpatient basis, and select patients are discharged within 24 hours of admission.
Regional Outlook of Benign Prostatic Hyperplasia Treatment Market
North America was the leading market for benign prostatic hyperplasia treatment in 2021. Aging population, increase in incidence of benign prostatic hyperplasia, and highly structured health care industry are augmenting the market in the region. Current disease trends indicate that the number of men with benign prostatic hyperplasia and lower urinary tract conditions will increase at a rapid pace in the U.S. in the near future. Rapidly aging population of the U.S. coupled with rise in diabetes and obesity is likely to drive the prevalence of benign prostatic hyperplasia and lower urinary tract conditions. Thus, demand for prostate hypertrophy treatment is estimated to increase in the U.S. in the near future.
Some of the prominent players in the Benign Prostatic Hyperplasia Treatment Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Benign Prostatic Hyperplasia Treatment market
By Geography
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Benign Prostatic Hyperplasia Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, 2017–2030
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Prevalence of Benign Prostatic Hyperplasia by region/globally
5.3. Re-imbursement Scenario
5.4. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.5. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, By Treatment
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Treatment, 2017–2030
6.3.1. Drug Class
6.3.1.1. Alpha-Blockers
6.3.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
6.3.1.3. Phosphodiesterase-5 Enzyme Inhibitor
6.3.1.4. Others
6.3.2. Minimally Invasive Surgeries
6.3.2.1. Transurethral Resection of the Prostate (TURP)
6.3.2.2. Transurethral Incision of the Prostate (TUIP)
6.3.2.3. Robotic Surgeries
6.3.2.4. Transurethral Microwave Thermotherapy (TUMT)
6.3.2.5. Prostatic Urethral Lift
6.3.3. Laser Therapy
6.3.4. Others
6.4. Market Attractiveness Analysis, by Treatment
7. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2030
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Treatment, 2017–2030
9.2.1. Drug Class
9.2.1.1. Alpha-Blockers
9.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
9.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
9.2.1.4. Others
9.2.2. Minimally Invasive Surgeries
9.2.2.1. Transurethral Resection of the Prostate (TURP)
9.2.2.2. Transurethral Incision of the Prostate (TUIP)
9.2.2.3. Robotic Surgeries
9.2.2.4. Transurethral Microwave Thermotherapy (TUMT
9.2.2.5. Prostatic Urethral Lift
9.2.3. Laser Therapy
9.2.4. Others
9.3. Market Value Forecast, by End-user, 2017–2030
9.3.1. Hospitals
9.3.2. Ambulatory Surgical Centers
9.3.3. Specialty Clinics
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017–2030
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Treatment
9.5.2. By End-user
9.5.3. By Country
10. Europe Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2017–2030
10.2.1. Drug Class
10.2.1.1. Alpha-Blockers
10.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
10.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
10.2.1.4. Others
10.2.2. Minimally Invasive Surgeries
10.2.2.1. Transurethral Resection of the Prostate (TURP)
10.2.2.2. Transurethral Incision of the Prostate (TUIP)
10.2.2.3. Robotic Surgeries
10.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
10.2.2.5. Prostatic Urethral Lift
10.2.3. Laser Therapy
10.2.4. Others
10.3. Market Value Forecast, by End-user, 2017–2030
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Specialty Clinics
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2030
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Treatment
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2017–2030
11.2.1. Drug Class
11.2.1.1. Alpha-Blockers
11.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
11.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
11.2.1.4. Others
11.2.2. Minimally Invasive Surgeries
11.2.2.1. Transurethral Resection of the Prostate (TURP)
11.2.2.2. Transurethral Incision of the Prostate (TUIP)
11.2.2.3. Robotic Surgeries
11.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
11.2.2.5. Prostatic Urethral Lift
11.2.3. Laser Therapy
11.2.4. Others
11.3. Market Value Forecast, by End-user, 2017–2030
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Specialty Clinics
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2030
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Treatment
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2017–2030
12.2.1. Drug Class
12.2.1.1. Alpha-Blockers
12.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
12.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
12.2.1.4. Others
12.2.2. Minimally Invasive Surgeries
12.2.2.1. Transurethral Resection of the Prostate (TURP)
12.2.2.2. Transurethral Incision of the Prostate (TUIP)
12.2.2.3. Robotic Surgeries
12.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
12.2.2.5. Prostatic Urethral Lift
12.2.3. Laser Therapy
12.2.4. Others
12.3. Market Value Forecast, by End-user, 2017–2030
12.3.1. Hospitals
12.3.2. Ambulatory Surgical Centers
12.3.3. Specialty Clinics
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2030
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Treatment
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Benign Prostatic Hyperplasia Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2017–2030
13.2.1. Drug Class
13.2.1.1. Alpha-Blockers
13.2.1.2. 5-Alpha-reductase Inhibitor (5-ARIs)
13.2.1.3. Phosphodiesterase-5 Enzyme Inhibitor
13.2.1.4. Others
13.2.2. Minimally Invasive Surgeries
13.2.2.1. Transurethral Resection of the Prostate (TURP)
13.2.2.2. Transurethral Incision of the Prostate (TUIP)
13.2.2.3. Robotic Surgeries
13.2.2.4. Transurethral Microwave Thermotherapy (TUMT)
13.2.2.5. Prostatic Urethral Lift
13.2.3. Laser Therapy
13.2.4. Others
13.3. Market Value Forecast, by End-user, 2017–2030
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers
13.3.3. Specialty Clinics
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2030
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Treatment
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Boston Scientific Corporation
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teleflex Incorporated
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Endo International plc
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Urologix, LLC
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.5. LISA Laser
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. Olympus Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers